Chidamide Combined With Linperlisibon for the Treatment of Refractory/Relapsed Follicular Lymphoma
Status:
Recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
To observe the safety and efficacy of Chidamide combined with Linperlisib in the treatment of
refractory and relapsed follicular lymphoma.
Phase:
Phase 2
Details
Lead Sponsor:
The First Affiliated Hospital of Xiamen University
Collaborators:
Dongguan People's Hospital Fujian Cancer Hospital Fujian Provincial Hospital Huizhou Municipal Central Hospital Jieyang People's Hospital Shanxi Province Cancer Hospital Sun Yat-sen University The First Affiliated Hospital with Nanjing Medical University Zhangzhou Affiliated Hospital of Fujian Medical University